• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

巨细胞病毒病作为接受靶向抗病毒和抗真菌预防的肝移植受者发生侵袭性真菌感染的危险因素。

Cytomegalovirus Disease as a Risk Factor for Invasive Fungal Infections in Liver Transplant Recipients under Targeted Antiviral and Antimycotic Prophylaxis.

作者信息

Breitkopf Robert, Treml Benedikt, Bukumiric Zoran, Innerhofer Nicole, Fodor Margot, Radovanovic Spurnic Aleksandra, Rajsic Sasa

机构信息

Department of Anesthesia and Intensive Care Medicine, Medical University Innsbruck, 6020 Innsbruck, Austria.

Institute of Medical Statistics and Informatics, Faculty of Medicine, University of Belgrade, 11000 Belgrade, Serbia.

出版信息

J Clin Med. 2023 Aug 9;12(16):5198. doi: 10.3390/jcm12165198.

DOI:10.3390/jcm12165198
PMID:37629240
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10455861/
Abstract

UNLABELLED

Cytomegalovirus (CMV) infection is the most common opportunistic infection that occurs following orthotopic liver transplantation (OLT). In addition to the direct infection-related symptoms, it also triggers an immunological response that may contribute to adverse clinical outcomes. CMV disease has been described as a predictor of invasive fungal infections (IFIs) but its role under an antiviral prophylaxis regimen is unclear.

METHODS

We retrospectively analyzed the medical records of 214 adult liver transplant recipients (LTRs). Universal antiviral prophylaxis was utilized in recipients with CMV mismatch; intermediate- and low-risk patients received pre-emptive treatment.

RESULTS

Six percent of patients developed CMV disease independent of their serostatus. The occurrence of CMV disease was associated with elevated virus load and increased incidence of leucopenia and IFIs. Furthermore, CMV disease was associated with higher one-year mortality and increased relapse rates within the first year of OLT.

CONCLUSIONS

CMV disease causes significant morbidity and mortality in LTRs, directly affecting transplant outcomes. Due to the increased risk of IFIs, antifungal prophylaxis for CMV disease may be appropriate. Postoperative CMV monitoring should be considered after massive transfusion, even in low-risk serostatus constellations. In case of biliary complications, biliary CMV monitoring may be appropriate in the case of CMV-DNA blood-negative patients.

摘要

未标注

巨细胞病毒(CMV)感染是原位肝移植(OLT)后最常见的机会性感染。除了与直接感染相关的症状外,它还引发免疫反应,这可能导致不良临床结局。CMV疾病已被描述为侵袭性真菌感染(IFI)的一个预测指标,但其在抗病毒预防方案下的作用尚不清楚。

方法

我们回顾性分析了214例成年肝移植受者(LTR)的病历。CMV配型不匹配的受者采用普遍抗病毒预防;中低风险患者接受抢先治疗。

结果

6%的患者发生了与血清学状态无关的CMV疾病。CMV疾病的发生与病毒载量升高、白细胞减少症和IFI发生率增加有关。此外,CMV疾病与较高的一年死亡率和OLT后第一年内复发率增加有关。

结论

CMV疾病在LTR中导致显著的发病率和死亡率,直接影响移植结局。由于IFI风险增加,对CMV疾病进行抗真菌预防可能是合适的。即使在低风险血清学状态的情况下,大量输血后也应考虑术后CMV监测。对于发生胆道并发症的患者,在CMV-DNA血检阴性的情况下,进行胆道CMV监测可能是合适的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c9b/10455861/0e0545ce9a4e/jcm-12-05198-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c9b/10455861/256af0ac4b9a/jcm-12-05198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c9b/10455861/0e0545ce9a4e/jcm-12-05198-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c9b/10455861/256af0ac4b9a/jcm-12-05198-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8c9b/10455861/0e0545ce9a4e/jcm-12-05198-g002.jpg

相似文献

1
Cytomegalovirus Disease as a Risk Factor for Invasive Fungal Infections in Liver Transplant Recipients under Targeted Antiviral and Antimycotic Prophylaxis.巨细胞病毒病作为接受靶向抗病毒和抗真菌预防的肝移植受者发生侵袭性真菌感染的危险因素。
J Clin Med. 2023 Aug 9;12(16):5198. doi: 10.3390/jcm12165198.
2
The association of cytomegalovirus infection and cytomegalovirus serostatus with invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients: a systematic review and meta-analysis.巨细胞病毒感染和巨细胞病毒血清状态与异基因造血干细胞移植受者侵袭性真菌感染的关系:系统评价和荟萃分析。
Clin Microbiol Infect. 2022 Mar;28(3):332-344. doi: 10.1016/j.cmi.2021.10.008. Epub 2021 Nov 6.
3
The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.巨细胞病毒作为原位肝移植受者侵袭性真菌病危险因素的独立作用。波士顿肝移植中心CMVIG研究组。赛美维,MedImmune公司,马里兰州盖瑟斯堡。
Am J Med. 1997 Aug;103(2):106-13. doi: 10.1016/s0002-9343(97)80021-6.
4
Acyclovir versus valganciclovir for preventing cytomegalovirus infection in intermediate-risk liver transplant recipients.阿昔洛韦与缬更昔洛韦预防中危肝移植受者巨细胞病毒感染的比较
Prog Transplant. 2015 Mar;25(1):39-44. doi: 10.7182/pit2015558.
5
Viral factors influencing the outcome of human cytomegalovirus infection in liver transplant recipients.影响肝移植受者人巨细胞病毒感染结局的病毒因素。
J Clin Virol. 2011 Aug;51(4):229-33. doi: 10.1016/j.jcv.2011.05.012. Epub 2011 Jun 8.
6
Early versus delayed initiation of cytomegalovirus prophylaxis after liver transplant.肝移植后尽早与延迟启动巨细胞病毒预防。
Pharmacotherapy. 2022 Aug;42(8):634-640. doi: 10.1002/phar.2714. Epub 2022 Jul 1.
7
Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.巨细胞病毒免疫球蛋白(CMVIG)预防与原位肝移植后生存率提高相关。波士顿肝移植中心CMVIG研究小组。
Clin Transplant. 1997 Oct;11(5 Pt 1):432-7.
8
The value of pre-emptive therapy for cytomegalovirus after liver transplantation.肝移植后巨细胞病毒抢先治疗的价值。
Transplant Proc. 2012 Jun;44(5):1357-61. doi: 10.1016/j.transproceed.2011.11.067.
9
Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients.荟萃分析:巨细胞病毒预防实体器官移植受者器官疾病策略的疗效
Ann Intern Med. 2005 Dec 20;143(12):870-80. doi: 10.7326/0003-4819-143-12-200512200-00005.
10
Cytomegalovirus infection after liver transplantation: current concepts and challenges.肝移植后的巨细胞病毒感染:当前概念与挑战
World J Gastroenterol. 2008 Aug 21;14(31):4849-60. doi: 10.3748/wjg.14.4849.

本文引用的文献

1
Invasive Fungal Infections: The Early Killer after Liver Transplantation.侵袭性真菌感染:肝移植后的早期杀手
J Fungi (Basel). 2023 Jun 12;9(6):655. doi: 10.3390/jof9060655.
2
Invasive Fungal Infections after Liver Transplantation.肝移植术后侵袭性真菌感染
J Clin Med. 2023 Apr 30;12(9):3238. doi: 10.3390/jcm12093238.
3
Invasive Fungal Breakthrough Infections under Targeted Echinocandin Prophylaxis in High-Risk Liver Transplant Recipients.高危肝移植受者接受靶向棘白菌素预防治疗下的侵袭性真菌突破性感染
J Fungi (Basel). 2023 Feb 18;9(2):272. doi: 10.3390/jof9020272.
4
Incidence of Invasive Fungal Infections in Liver Transplant Recipients under Targeted Echinocandin Prophylaxis.接受棘白菌素靶向预防的肝移植受者侵袭性真菌感染的发生率
J Clin Med. 2023 Feb 14;12(4):1520. doi: 10.3390/jcm12041520.
5
Cytomegalovirus DNAemia Requiring (Val)Ganciclovir Treatment for More Than 8 Weeks Is a Key Factor in the Development of Antiviral Drug Resistance.需要(缬氨)更昔洛韦治疗超过8周的巨细胞病毒血症是抗病毒药物耐药性产生的关键因素。
Open Forum Infect Dis. 2023 Jan 23;10(2):ofad018. doi: 10.1093/ofid/ofad018. eCollection 2023 Feb.
6
New Insights on CMV Management in Solid Organ Transplant Patients: Prevention, Treatment, and Management of Resistant/Refractory Disease.实体器官移植患者巨细胞病毒管理的新见解:耐药/难治性疾病的预防、治疗与管理
Infect Dis Ther. 2023 Feb;12(2):333-342. doi: 10.1007/s40121-022-00746-1. Epub 2022 Dec 30.
7
Post-transplant biliary complications: advances in pathophysiology, diagnosis, and treatment.移植后胆道并发症:病理生理学、诊断和治疗的进展。
BMJ Open Gastroenterol. 2022 May;9(1). doi: 10.1136/bmjgast-2021-000778.
8
Impact of cytomegalovirus infection on biliary disease after liver transplantation - maybe an essential factor.巨细胞病毒感染对肝移植后胆道疾病的影响——可能是一个关键因素。
World J Clin Cases. 2021 Dec 16;9(35):10792-10804. doi: 10.12998/wjcc.v9.i35.10792.
9
Outcomes among CMV-mismatched and highly sensitized kidney transplants recipients who develop neutropenia.巨细胞病毒(CMV) mismatched 和高度致敏的肾移植受者中性粒细胞减少症的结局。
Clin Transplant. 2022 Apr;36(4):e14583. doi: 10.1111/ctr.14583. Epub 2022 Jan 15.
10
Diagnostic Modalities in Critical Care: Point-of-Care Approach.重症监护中的诊断方法:床旁检测法
Diagnostics (Basel). 2021 Nov 25;11(12):2202. doi: 10.3390/diagnostics11122202.